Table 2 Distribution of the studies and patients across the different subgroups and analyses.
Subgroup | Response rate analysis reports | Survival analysis reports | ||||||
|---|---|---|---|---|---|---|---|---|
N (%) | Pt enrolled | N (%) | Pt infused | OS | EFS | |||
N (%) | Pt | N (%) | Pt | |||||
Domain | 29 | 32 | 23 | 21 | ||||
4-1BB | 24 (83) | 1309 | 27 (84) | 1289 | 18 (78) | 1035 | 17 (81) | 946 |
CD28 | 5 (17) | 257 | 5 (16) | 202 | 5 (22) | 195 | 4 (19) | 172 |
Age group | 36 | 38 | 25 | 22 | ||||
Pediatric/young adult (≤ 25) | 11 (31) | 420 | 11 (30) | 354 | 5 (20) | 202 | 4 (18) | 149 |
Mixed (≤ 25 and/or >25) | 25 (69) | 1646 | 27 (71) | 1554 | 20 (80) | 1317 | 18 (82) | 1223 |
Disease morphology | 33 | 35 | 25 | 22 | ||||
Remission (BMB < 5%) | 9 (27) | 464 | 10 (29) | 485 | 7 (28) | 453 | 7 (32) | 453 |
Disease (BMB ≥ 5%) | 24 (73) | 1478 | 25 (71) | 1303 | 18 (72) | 1066 | 15 (68) | 919 |
LD dose (Cy total dosea) | 28 | 30 | 23 | 20 | ||||
High (≥1500 mg/m2) | 11 (39) | 602 | 11 (37) | 494 | 10 (43) | 444 | 8 (40) | 323 |
Low (<1500 mg/m2) | 17 (61) | 945 | 19 (63) | 926 | 13 (57) | 803 | 12 (60) | 777 |
Report type | 35 | 38 | 25 | 22 | ||||
Clinical trial | 32 (91) | 1556 | 35(92) | 1437 | 22 (88) | 1055 | 19 (86) | 908 |
RWD | 3 (9) | 488 | 3 (8) | 471 | 3 (12) | 464 | 3 (14) | 464 |
